Literature DB >> 17980954

Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.

Gerhard Feil1, Sabine Maurer, Udo Nagele, Jutta Krug, Conny Bock, Karl-Dietrich Sievert, Arnulf Stenzl.   

Abstract

OBJECTIVE: To investigate the immunoreactivity of p63 in monolayered and stratified human urothelial cell cultures and in normal urothelial tissues to assess the differentiation status of in vitro stratified urothelial constructs.
METHODS: p63 expression was detected immunohistochemically in native normal human bladder, ureter, and renal pelvis tissues and immunocytochemically in monolayered urothelial cell cultures and urothelial constructs stratified in vitro. Additionally, expression of pancytokeratin, cytokeratin 20 (CK20), uroplakin III, and fibroblast surface antigen was investigated.
RESULTS: In native tissues, urothelial cell layers showed the most intensive p63 staining in the basal cells; the superficial umbrella cells were predominantly negative. Monolayered urothelial cell cultures revealed reduced p63 expression with ongoing culture passages. In vitro stratified urothelial constructs exhibited p63 expression similar to that of native urothelium. CK20-reactive cells were absent in the monolayered cultures but present in the stratified cell cultures and in the urothelial constructs. In native urothelium, only superficial cells stained positive for CK20. Uroplakin III was not present in either monolayered urothelial cell cultures or stratified urothelial constructs. Cultured cells were always positive for pancytokeratin and negative for fibroblast surface antigen.
CONCLUSIONS: p63 is a new biomarker for differentiation and stratification of urothelium created in vitro. For proposed clinical applications of in vitro stratified urothelium in reconstructive urology, urothelial constructs should exhibit expression of significant marker proteins similar to that of native urothelium. Our results show such similarity of expression for pancytokeratin, p63, and CK20, an encouraging possibility for confirming the functionality of tissue-engineered urothelia after clinical application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17980954     DOI: 10.1016/j.eururo.2007.10.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  [Bioartificial urothelium generated from bladder washings. A future therapeutic option for reconstructive surgery].

Authors:  G Feil; S Maurer; U Nagele; K-D Sievert; A Stenzl
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

2.  A urine-dependent human urothelial organoid offers a potential alternative to rodent models of infection.

Authors:  Harry Horsley; Dhanuson Dharmasena; James Malone-Lee; Jennifer L Rohn
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

Review 3.  The relationship of cancer stem cells in urological cancers.

Authors:  Jan Adamowicz; Marta Pokrywczyńska; Jakub Tworkiewicz; Zbigniew Wolski; Tomasz Drewa
Journal:  Cent European J Urol       Date:  2013-11-18

4.  Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free system.

Authors:  Minyong Kang; Hyeon Hoe Kim; Yong-Mahn Han
Journal:  Int J Mol Sci       Date:  2014-04-25       Impact factor: 5.923

5.  Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.

Authors:  Carl Fishwick; Janet Higgins; Lawrence Percival-Alwyn; Arianna Hustler; Joanna Pearson; Sarah Bastkowski; Simon Moxon; David Swarbreck; Chris D Greenman; Jennifer Southgate
Journal:  Cell Death Differ       Date:  2017-03-10       Impact factor: 15.828

Review 6.  Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems.

Authors:  Benjamin O Murray; Carlos Flores; Corin Williams; Deborah A Flusberg; Elizabeth E Marr; Karolina M Kwiatkowska; Joseph L Charest; Brett C Isenberg; Jennifer L Rohn
Journal:  Front Cell Infect Microbiol       Date:  2021-05-26       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.